LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with a 10% YoY revenue increase, improved margins, and positive net income growth. Strategic initiatives for market expansion and product innovation, along with optimistic revenue and margin projections for 2026, further enhance the outlook. Despite some regulatory risks, the overall sentiment is positive, supported by robust financial metrics and strategic plans. The market cap suggests moderate stock price sensitivity, leading to a positive prediction.
Key Financial Performance
Revenue Revenue for Q4 2025 was $50 million, up 10% year-over-year, driven by strong sales in the North American market and successful product launches.
Gross Margin Gross margin improved to 65%, a 2% increase from the previous year, due to cost efficiencies and favorable product mix.
Operating Income Operating income was $12 million, representing a 20% increase year-over-year, attributed to higher revenue and controlled operating expenses.
Net Income Net income for the quarter was $9 million, up 15% compared to Q4 2024, primarily due to improved operating performance.
Cash Flow Cash flow from operations was $11 million, a 10% increase year-over-year, reflecting strong collections and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Explicit Risks: Forward-looking statements are subject to risks and uncertainties, as mentioned in the safe harbor statement. These include factors that could cause results to differ materially from expectations.
Regulatory Risks: Potential risks related to compliance with the U.S. Private Securities Litigation Reform Act of 1995 and other regulatory requirements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: LeMaitre Vascular is focusing on expanding its product portfolio and entering new markets. The company is planning to launch new products in the vascular surgery space, aiming to capture a larger market share. Additionally, they are exploring strategic acquisitions to enhance their growth trajectory.
Revenue Expectations: The company expects a revenue growth of 8-10% for the fiscal year 2026, driven by new product launches and expansion into emerging markets.
Margin Projections: LeMaitre Vascular anticipates an improvement in operating margins by 1-2 percentage points in 2026, supported by cost optimization initiatives and increased operational efficiency.
Capital Expenditures: The company plans to increase capital expenditures by 15% in 2026 to support infrastructure development and capacity expansion.
Market Trends: LeMaitre Vascular expects a recovery in the vascular surgery market, with increasing demand for minimally invasive procedures. The company is positioning itself to leverage these trends through innovation and strategic partnerships.
Business Segment Performance: The endovascular and biologics segments are projected to experience the highest growth rates in 2026, driven by product innovation and market expansion efforts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bauser ROTH
Brett Fishbin
CEO Roberts
Chairman CEO
Director Kyle
Division Brett
Division Frederick
Division Jakub
Division Petusky
Division Sarcone
Division Sidoti
Division Stauder
EST LeMaitre
Frederick Wise
George LeMaitre
Inc Research
Incorporated Research
Jakub Mlejnek
Jefferies LLC
Kyle Bauser
LLC PM
LLC Research
LeMaitre Chairman
LeMaitre Vascular
Mlejnek Oppenheimer
Nicolaus Incorporated
Officer George
Officer LeMaitre
PM EST
Petusky Barrington
President Director
Research Division
Sidoti LLC
Stifel Nicolaus
LMAT Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
Positive5-6
The financial performance was robust with significant year-over-year increases in revenue, gross margin, operating income, net income, and EPS. The company also demonstrated strong cash flow from operations. These positive results, coupled with the market cap of a small-cap stock, suggest a strong positive stock price reaction over the next two weeks.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 20% YoY revenue increase and a transition to net income from a loss. The optimistic guidance for operating income growth and EPS, along with strategic initiatives like sales force expansion and new distribution centers, contribute to a positive outlook. However, the absence of discussions on shareholder returns and potential risks tempers the sentiment slightly. Given the market cap, the stock is likely to see a positive movement (2% to 8%) over the next two weeks.
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 10% YoY revenue increase, improved margins, and positive net income growth. Strategic initiatives for market expansion and product innovation, along with optimistic revenue and margin projections for 2026, further enhance the outlook. Despite some regulatory risks, the overall sentiment is positive, supported by robust financial metrics and strategic plans. The market cap suggests moderate stock price sensitivity, leading to a positive prediction.
LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
Positive11-7
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
LMAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
